# Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C

> **NCT00621296** · PHASE2 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 15 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** MP-424 (Telaprevir)

## Key facts

- **NCT ID:** NCT00621296
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- Vertex Pharmaceuticals Incorporated

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00621296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00621296, "Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00621296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*